Invea Therapeutics

Overview We are a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs. Our aim is to develop oral, safe and effective small-molecule therapies that control inflammation, prevent tissue damage, improve quality of life and achieve long-term disease remission. We believe that the lack of an in-depth understanding of the pathophysiological mechanisms underlying immune-mediated inflammation has restricted therapeutic options for several IMIDs to merely symptomatic interventions, with limited effectiveness. Our drug discovery and development approach combines artificial intelligence, or AI, and machine learning, or ML, with our teams extensive experience and expertise, to decode the mechanisms...

Drug discovery ,target discovery,inflammation,immune-mediated inflammatory diseases,oral small molecules,atopic dermatitis,chronic urticaria,and imids

Invea therapeutics operates in the Biotechnology industry.

Invea therapeutics's revenue is 11m - 100m

Invea therapeutics has 11 - 50 employees.